SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?

摘要: Sodium-glucose transporter-2 (SGLT-2) inhibitors have emerged as novel oral glucose-lowering agents for type 2 diabetes. SGLT-2 improve glycemic control by blocking sodium-glucose cotransport in the renal proximal tubules, thereby promoting glycosuria. In this review, it is discussed mechanistically how might be particularly relevant to use patients with or at high risk heart failure. On a daily base, block ~330–495 mEq sodium reabsorbed although substantial amounts can more distally nephron. Increased offering distal nephron sensed macula densa and may attenuate neurohumoral activation, improving salt sensitivity, augmenting diuretic efficacy of loop thiazide diuretics, potentiating native natriuretic peptide system. Whether favorable profile offered renoprotective whether inhibition relieve and/or prevent congestion beyond traditional drugs warrants further investigation.